BioAdvance News Portfolio News Relmada Therapeutics

Relmada Therapeutics Announces Top-line Results from Phase 3 RELIANCE I Trial for REL-1017 as an Adjunctive Treatment for Major Depressive Disorder

By WebmasterDecember 7, 2022November 1st, 2024No Comments

Relmada Therapeutics Announces Top-line Results from Phase 3 RELIANCE I Trial for REL-1017 as an Adjunctive Treatment for Major Depressive Disorder

See more here

Previous PostSenzo Secures Additional $1.9MM Equity Funding for Its PCR-Accurate Lateral Flow Test
Next PostMebias Discovery Initiates a Phase I Clinical Trial of MEB-1170, a Novel Analgesic Drug Candidate for the Treatment of Pain and Prevention of Opioid Use Disorder

Relmada Therapeutics Announces Top-line Results from Phase 3 RELIANCE I Trial for REL-1017 as an Adjunctive Treatment for Major Depressive Disorder

SEARCH

TOPICS

ARCHIVES

RECENT POSTS

Previous PostSenzo Secures Additional $1.9MM Equity Funding for Its PCR-Accurate Lateral Flow Test

Next PostMebias Discovery Initiates a Phase I Clinical Trial of MEB-1170, a Novel Analgesic Drug Candidate for the Treatment of Pain and Prevention of Opioid Use Disorder